Weight-loss drug Belviq seems safe for heart, study finds

August 26, 2018 by Marilynn Marchione
This undated image provided by Eisai in August 2018 shows the company's Belviq medication. For the first time, a study found that a drug can help people lose weight and keep it off for several years without raising their risk for heart problems. Doctors say the results may encourage wider use of Belviq to help fight obesity. Results were discussed Sunday, Aug 26, 2018 at a European Society of Cardiology meeting in Munich and published by the New England Journal of Medicine. (Eisai via AP)

For the first time, a drug has been shown to help people lose weight and keep it off for several years without raising their risk for heart problems—a safety milestone that may encourage wider use to help curb the obesity epidemic.

The drug, Belviq, has been sold in the United States since 2013 and is the first of several new weight-loss medicines to complete a long-term heart safety study now required by federal regulators to stay on the market.

"Patients and their doctors have been nervous about using drugs to treat obesity and for good reason. There's a history of these drugs having serious complications," said study leader Dr. Erin Bohula of Brigham and Women's Hospital in Boston.

With this study, Belviq has been convincingly shown safe for the heart, she said.

Although Belviq did not raise heart risks, it didn't lower them either, as many had hoped it would. The weight loss it produced was fairly modest—after 40 months, Belviq users had shed 9 pounds (4 kilograms), twice as much as those on dummy pills.

It may be that weight loss alone is not enough to lower heart risks, or that there needs to be more to do that, some doctors said.

Results were discussed Sunday at a European Society of Cardiology meeting in Munich and published by the New England Journal of Medicine. Belviq's maker, Eisai Inc., sponsored the study and many of the researchers consult or work for the company.

Worldwide, 13 percent of adults are obese and 39 percent are overweight, raising their risk for a host of health problems. Diet and exercise are the first steps doctors recommend, but medicines also can be considered for people with dangerously high weight who cannot drop enough pounds by other means.

Several popular diet medicines were previously withdrawn from sale after they were found to raise the risk for , suicidal thoughts or other problems, prompting the new requirement for heart safety studies.

Belviq is an appetite suppressant that works by stimulating brain chemicals to give a feeling of fullness. It costs roughly $220 to $290 a month in the United States.

Researchers tested it in a study of 12,000 people who were either obese or overweight with heart disease risk factors such as high blood pressure or cholesterol. They were given Belviq or dummy pills to take twice a day and offered lifestyle and diet advice.

At one year, 39 percent on Belviq and 17 percent on dummy pills had lost at least 5 percent of their starting weight. Several previous studies also found the drug effective for weight loss.

After about three years, 6 percent of each group had suffered a heart-related problem or death.

Fewer people on Belviq developed diabetes—8.5 percent versus 10.3 percent on dummy pills.

Serious side effects were similar, but more on Belviq stopped taking their pills because of them—7 percent versus 4 percent. Common side effects included dizziness, fatigue, headache and nausea.

Dangerously low blood sugar happened in 13 people on Belviq versus four in the other group; all but one case involved people also taking diabetes medicines, which lower blood sugar.

Tests for heart valve damage were done on 3,270 participants but no big differences in rates were seen. Suicidal thoughts or behavior were reported in 21 people on Belviq versus 11 on dummy pills, but more on the drug had a history of depression and the difference was so small it could have been due to chance, Bohula said.

In a commentary, two of the journal's editors, Drs. Julie Inglefinger and Clifford Rosen, said there might be alternatives to Belviq. Liraglutide, when used to treat diabetes, also causes loss and lowers risks, though it hasn't been tested for cardiac safety at the dose used for .

For now, Belviq "may be best used on a cautious basis, according to the needs of individual patients," they write.

Explore further: Weight loss drug Belviq gets overdue US launch

Related Stories

Weight loss drug Belviq gets overdue US launch

June 7, 2013
Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators.

Arena Pharmaceuticals shares rise on weight loss drug patent

April 7, 2015
Shares of Arena Pharmaceuticals rose Tuesday after the drug developer said it received an additional patent for its weight loss drug Belviq.

US clears first new weight-loss pill in 13 years

June 27, 2012
(AP) — The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

FDA approves weight-loss drug Contrave (Update)

September 11, 2014
U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

Five diet drugs: which ones work?

June 14, 2016
(HealthDay)—Any of the prescription weight-loss drugs on the market can help obese people shed pounds, although some seem more effective than others, a new study finds.

FDA approves highly anticipated weight-loss pill

July 18, 2012
(AP) — The Food and Drug Administration on Tuesday approved a new weight loss drug from Vivus Inc. that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients ...

Recommended for you

Height may be risk factor for varicose veins, study finds

September 24, 2018
The taller you are, the more likely you are to develop varicose veins, according to a study led by Stanford University School of Medicine researchers that examined the genes of more than 400,000 people in search of clues ...

Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death

September 24, 2018
In the largest multi-institutional study to date, led by researchers from Penn Medicine, the team found that among patients who underwent a transcatheter aortic valve replacement (TAVR), a high number experienced severe and ...

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Can a common heart condition cause sudden death?

September 20, 2018
About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions ...

New drugs could reduce risk of heart disease when added to statins

September 20, 2018
New drugs that lower levels of triglycerides (a type of fat) in blood could further reduce the risk of heart attack when added to statins. These new drugs, which are in various stages of development, could also reduce blood ...

Mediterranean-style diet may lower women's stroke risk

September 20, 2018
Following a Mediterranean-style diet may reduce stroke risk in women over 40 but not in men—according to new research led by the University of East Anglia.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tekram
not rated yet Aug 26, 2018
Lorcaserin is classified as a Schedule IV drug because it has hallucinogenic properties at higher than approved doses and users could develop psychiatric dependencies on the drug. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor.

The 5-HT2A receptor is the target of serotonergic psychedelic drugs such as LSD.

You are better off just following a low fat diet which will reduce your craving for more food and save more than $300 a month in Belviq and fat.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.